Early November 2011, Global Compact participant GlaxoSmithKline announced it would pay USD 3 billion to resolve federal government civil and criminal investigations into its sales practices for numerous drugs. The cases included allegations of illegal selling of Avandia, a diabetes drug linked to heart risks, as well as paying doctors and manipulating medical research to promote the drug.
GlaxoSmithKline is a Global Compact participant since 2007/08/10
Read more
No comments:
Post a Comment